Richard Pazdur (Flatiron Health via YouTube)
February 9, 2022 10:47 AM EST
FDA+

Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

Kyle Blankenship

Eli Lil­ly has a big de­ci­sion com­ing Thurs­day as an FDA ad­vi­so­ry com­mit­tee con­sid­ers the mer­its of PD-1 block­er sin­til­imab, a drug de­vel­oped in Chi­na …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

A service from the Financial Times